Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis

Hayes Jr., Don; Feola, David J.; Murphy, Brian S.; Kuhn, Robert J.; Davis, George A.
February 2011
American Journal of Health-System Pharmacy;2/15/2011, Vol. 68 Issue 4, p319
Academic Journal
Purpose. The use of a continuous infusion of a ß-lactam antibiotic in combination with high-dose, extended-interval aminoglycoside therapy for eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis (CF) is reported. Summary. Testing of an expectorated sputum sample taken during routine evaluation of a 32-year-old woman with CF isolated P. aeruginosa; the patient's medical record indicated no prior episodes of P. aeruginosa colonization. In an initial attempt to eradicate the organism, the woman received outpatient therapy with oral ciprofloxacin twice daily combined with an minoglycoside (tobramycin solution) by nebulization twice daily. After a culture four weeks later again isolated P. aeruginosa, the patient was hospitalized, and i.v. antimicrobial therapy was initiated. The inpatient treatment regimen consisted of continuous-infusion cefepime 6 g (100 mg/kg/24 hr) and i.v. tobramycin 700 mg (12 mg/kg/24 hr), with both drugs administered via a peripherally inserted central catheter, for two weeks. A bronchoalveolar lavage fluid culture performed two months after completion of the i.v. antimicrobial regimen, as well as several sputum cultures obtained during the subsequent three years, tested negative for P. aeruginosa. Conclusion. The administration of continuous-infusion cefepime and highdose, extended-interval tobramycin led to the successful eradication of P. aeruginosa in an adult patient with CF.


Related Articles

  • Ceftolozane/Tazobactam. Cada, Dennis J.; Wageman, Jesse; Baker, Danial E.; Levien, Terri L. // Hospital Pharmacy;Jun2015, Vol. 50 Issue 6, p526 

    The article offers information on the drug ceftolozane/tazobactam used as anti-infective agent. Topics discussed include the use of the drug in disease like urinary tract infections (UTIs), clinical pharmacology of the drug, effectiveness of ceftolozane/tazobactam against gram-negative bacilli,...

  • IV treatment for bacterial infections.  // Clinical Advisor;Feb2011, Vol. 14 Issue 2, p29 

    The article offers brief information on Teflaro from Forest Laboratories Inc.

  • Pneumonia during the treatment of acute leukemia.  // British Medical Journal;11/8/1980, Vol. 281 Issue 6250, p1235 

    Examines the influence of pneumonia on the illness and mortality among patients with acute leukemia being treated with chemotherapy. Increase of infection with the degree of neutropenia; Production of sputum and radiological signs of pneumonia; Effectiveness on the combination of tobramycin and...

  • TOBI helps patients with cystic fibrosis. Cerrato, Paul L. // RN;Apr99, Vol. 62 Issue 4, p96 

    Presents excerpts from the paper `Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis,' by B.W. Ramsey, M.S. Pepe, et al, published in the `New England Journal of Medicine' magazine. Use of inhaled tobramycin in treatment of cystic fibrosis.

  • Successful implementation of infection control strategies prevents P. aeruginosa transmission among cystic fibrosis patients inside the hospital. Matt, Benedikt; Mitteregger, Dieter; Renner, Sabine; Presterl, Elisabeth; Assadian, Ojan; Diab-Elschahawi, Magda // GMS Hygiene & Infection Control;2014, Vol. 9 Issue 3, p1 

    Background: The aim of this study was to characterise the epidemiology of P. aeruginosa isolated from cystic fibrosis (CF) patients at the Vienna General Hospital (VGH) by molecular genetic fingerprinting in order to understand transmission ways and to evaluate the established infection control...

  • Novel combination of two drugs improves lung function.  // BMJ: British Medical Journal;5/23/2015, Vol. 350 Issue 8009, ph2689 

    The article discusses research being done which examined the efficacy of a combination of two drugs, used to correct levels of the transmembrane protein, to treat patients with cystic fibrosis, as reported in the "New England Journal of Medicine."

  • Population pharmacokinetics of continuous infusion ceftazidime. Frame, B.C.; Facca, B.F.; Nicolau, D.P.; Triesenberg, S.N. // Clinical Pharmacokinetics;1999, Vol. 37 Issue 4, p343 

    Objective: The purpose of this study was to develop and validate a model that predicts clearance and steady-state ceftazidime concentrations during continuous infusion.Design: This was a prospective clinical observational trial. Two models describing drug clearance...

  • Inhaled Tobramycin (TOBI®): A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis. Cheer, Susan M.; Waugh, John; Noble, Stuart // Drugs;2003, Vol. 63 Issue 22, p2501 

    Specifically formulated for nebulisation using the PARI LC PLUS™ reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI[sup ®]] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients...

  • Cystic Fibrosis Drug Combination Shows Promise.  // AARC Times;Sep2015, Vol. 39 Issue 9, p60 

    The article discusses the results of the clinical trials of a new drug for people with cystic fibrosis.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics